Familial Adenomatous Polyposis Treatment

Familial adenomatous polyposis (FAP) is an inherited colorectal cancer predisposition syndrome most commonly associated with pathogenic variants in the APC gene. Effective management requires lifelong surveillance and coordinated care because affected individuals can develop hundreds to thousands of colorectal adenomas, along with extracolonic manifestations. Treatment decisions generally combine endoscopic management, prophylactic colorectal surgery, pathology review, genetic counseling, and monitoring for upper gastrointestinal and other disease features.

FAP management is shifting from reactive treatment of advanced polyposis toward structured, genotype-informed prevention. Earlier genetic evaluation, cascade testing for relatives, standardized colonoscopic surveillance, and referral to specialized hereditary cancer services are strengthening risk identification. Surgical planning is also becoming more individualized, balancing cancer prevention with bowel function, fertility considerations, quality of life, and the burden of future endoscopic surveillance. Multidisciplinary pathways increasingly connect gastroenterology, colorectal surgery, genetics, oncology, pathology, nutrition, and psychosocial support.

Artificial intelligence may augment FAP care by supporting adenoma detection during colonoscopy, improving image review, prioritizing lesions for assessment, and assisting documentation and risk stratification. In hereditary polyposis, its value depends on performance across varied bowel-preparation quality, lesion morphologies, imaging platforms, and patient populations. AI should remain an adjunct to expert endoscopists and multidisciplinary judgment, with validation, privacy safeguards, explainability, and prospective evidence required before integration into routine hereditary cancer pathways.

North America generally benefits from established genetic counseling, advanced endoscopy, colorectal surgery, and hereditary cancer programs, although insurance coverage and geographic access remain important barriers. Europe combines mature specialist services with variation among national health systems, referral pathways, and availability of genetic testing. Asia-Pacific includes highly developed centers alongside areas where diagnosis and surveillance capacity are limited, making referral networks and workforce development important. Latin America continues to face disparities in genetic services, pathology capacity, and access to prophylactic surgery. In the Middle East, specialized centers and family-based care can support management, while referral concentration and uneven testing access remain challenges. Africa requires stronger awareness, diagnostic infrastructure, genetic counseling capacity, and access to coordinated long-term surveillance.

Across ASEAN, FAP management is influenced by differences in specialist availability, public-sector capacity, and access to molecular testing. BRICS countries encompass substantial variation in referral systems, urban-rural access, and the integration of genetics into routine care. European Union members benefit from cross-border clinical knowledge and shared professional guidance, while national reimbursement and service organization still differ. G7 systems generally have advanced diagnostic and surgical capabilities but continue to address affordability, wait times, and equitable access. GCC countries are strengthening specialist and genomic medicine capacity, with family-based risk assessment particularly relevant. NATO members span diverse health systems, so implementation of consistent hereditary cancer pathways remains dependent on national policy and local clinical infrastructure.

Australia has established hereditary cancer services, with challenges related to distance and access outside major centers. Brazil and Mexico continue to emphasize earlier recognition, referral, and broader access to genetic counseling and specialist surgery. Canada and the United States have substantial expertise in genetic testing, endoscopy, and colorectal surgery, while coverage and regional availability can differ. China and India face large population needs alongside uneven specialist and molecular diagnostic capacity. Japan and South Korea have strong advanced-care capabilities, with continued emphasis on coordinated hereditary disease pathways. France, Germany, Italy, and Spain provide specialist gastroenterology and surgical services within distinct national systems, with variation in referral and reimbursement practices. The United Kingdom has structured clinical genetics and surveillance pathways, while Russia faces geographic and infrastructure differences that can affect continuity of specialist care.

Industry and health-system leaders should strengthen referral networks that connect primary care, gastroenterology, genetics, colorectal surgery, pathology, and psychosocial services. Expand cascade testing and counseling with clear consent, privacy, and family communication processes, while improving access for rural and underserved populations through telehealth and regional partnerships. Standardize surveillance documentation, surgical decision support, and follow-up for extracolonic disease. Evaluate AI only through clinically relevant validation and governance frameworks. Patient-centered outcomes-including bowel function, fertility, quality of life, adherence, and psychological well-being-should complement adenoma and cancer-prevention measures when assessing care pathways.

This executive summary synthesizes established clinical concepts for FAP management, including inherited risk, surveillance, endoscopic therapy, prophylactic colorectal surgery, genetic counseling, and multidisciplinary follow-up. Regional, group, and country observations are framed as health-system and access considerations rather than quantitative market claims. The analysis avoids market estimates, market shares, forecasts, and company-specific assessments. Interpretation should be updated against current clinical guidelines, regulatory requirements, peer-reviewed evidence, and locally applicable care standards.

FAP treatment is fundamentally a prevention and continuity-of-care challenge. Outcomes depend on identifying affected families early, maintaining reliable surveillance, selecting surgery at an appropriate stage, and monitoring extracolonic manifestations throughout life. Progress will require coordinated specialist pathways, equitable access to genetic and endoscopic services, careful use of digital tools, and decisions that reflect both cancer risk and patient quality of life. Health systems that connect these elements can improve consistency of care while adapting management to individual and family needs.